-
EP3423085
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3423085
| EP3423085 - PEPTIDES, COMBINATION OF PEPTIDES, AND CELL BASED MEDICAMENTS FOR USE IN IMMUNOTHERAPY AGAINST URINARY BLADDER CANCER AND OTHER CANCERS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 10.09.2021 Database last updated on 15.06.2024 | |
| Former | Examination is in progress Status updated on 05.11.2020 | ||
| Former | Request for examination was made Status updated on 07.12.2018 | ||
| Former | The international publication has been made Status updated on 08.09.2017 | ||
| Former | unknown Status updated on 10.03.2017 | Most recent event Tooltip | 10.09.2021 | Application deemed to be withdrawn | published on 13.10.2021 [2021/41] | Applicant(s) | For all designated states Immatics Biotechnologies GmbH Paul-Ehrlich-Strasse 15 72076 Tübingen / DE | [2019/02] | Inventor(s) | 01 /
MAHR, Andrea Kirschenweg 22 72076 Tübingen / DE | 02 /
WEINSCHENK, Toni Im Morgenrain 15 73773 Aichwald / DE | 03 /
SONG, Colette Willi-Baumeister-Weg 21 73760 Ostfildern / DE | 04 /
SCHOOR, Oliver Eichhaldenstrasse 19 72074 Tübingen / DE | 05 /
FRITSCHE, Jens Lärchenweg 11 72144 Dusslingen / DE | 06 /
SINGH, Harpreet Heckscherstr. 25a 80804 München / DE | [2019/02] | Representative(s) | Michalski Hüttermann & Partner Patentanwälte mbB Kaistraße 16A 40221 Düsseldorf / DE | [N/P] |
| Former [2019/02] | Krauss, Jan Boehmert & Boehmert Anwaltspartnerschaft mbB Pettenkoferstrasse 22 80336 München / DE | Application number, filing date | 17707843.3 | 28.02.2017 | [2019/02] | WO2017EP54559 | Priority number, date | GB20160003568 | 01.03.2016 Original published format: GB 201603568 | US201662302010P | 01.03.2016 Original published format: US 201662302010 P | [2019/02] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2017148888 | Date: | 08.09.2017 | Language: | EN | [2017/36] | Type: | A1 Application with search report | No.: | EP3423085 | Date: | 09.01.2019 | Language: | EN | The application published by WIPO in one of the EPO official languages on 08.09.2017 takes the place of the publication of the European patent application. | [2019/02] | Search report(s) | International search report - published on: | EP | 08.09.2017 | Classification | IPC: | A61K39/00, C07K14/47, C07K7/06 | [2019/02] | CPC: |
A61K39/0011 (EP,IL,KR,US);
C07K7/08 (IL,KR,US);
C07K7/06 (EP,IL,KR,US);
A61K35/17 (EP,IL,KR,US);
A61P35/00 (EP);
A61P37/04 (EP);
C07K14/4748 (EP,IL,KR,US);
C07K14/7051 (EP,IL,KR,US);
C07K16/18 (IL,KR,US);
C12N15/115 (IL,KR,US);
G01N33/6893 (IL,KR,US);
A61K2035/124 (IL,US);
A61K2039/5154 (EP,IL,KR,US);
A61K2039/80 (EP,US);
A61K2039/804 (EP,US);
A61K2039/812 (EP,US);
A61K2039/82 (EP,US);
A61K2039/828 (EP,US);
A61K2039/836 (EP,US);
A61K2039/844 (EP,US);
A61K2039/852 (EP,US);
A61K2039/86 (EP,US);
A61K2039/868 (EP,US);
A61K2039/876 (EP,US);
A61K2039/884 (EP,US);
A61K2039/892 (EP,US);
C07K2319/00 (EP,IL,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/02] | Extension states | BA | 19.09.2018 | ME | 19.09.2018 | Validation states | MA | 19.09.2018 | MD | 19.09.2018 | Title | German: | PEPTIDE, KOMBINATION VON PEPTIDEN UND AUF ZELLEN BASIERENDE ARZNEIMITTELN ZUR VERWENDUNG IN DER IMMUNTHERAPIE GEGEN BLASENKREBS UND ANDERE KREBSERKRANKUNGEN | [2019/02] | English: | PEPTIDES, COMBINATION OF PEPTIDES, AND CELL BASED MEDICAMENTS FOR USE IN IMMUNOTHERAPY AGAINST URINARY BLADDER CANCER AND OTHER CANCERS | [2019/02] | French: | PEPTIDES, COMBINAISON DE PEPTIDES ET MÉDICAMENTS À BASE DE CELLULES DESTINÉS À ÊTRE UTILISÉS EN IMMUNOTHÉRAPIE CONTRE LE CANCER DE LA VESSIE ET D'AUTRES CANCERS | [2019/02] | Entry into regional phase | 19.09.2018 | National basic fee paid | 19.09.2018 | Designation fee(s) paid | 19.09.2018 | Examination fee paid | Examination procedure | 19.09.2018 | Examination requested [2019/02] | 19.09.2018 | Date on which the examining division has become responsible | 09.04.2019 | Amendment by applicant (claims and/or description) | 04.11.2020 | Despatch of a communication from the examining division (Time limit: M06) | 15.05.2021 | Application deemed to be withdrawn, date of legal effect [2021/41] | 09.06.2021 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2021/41] | Divisional application(s) | EP21171324.3 / EP3915577 | Fees paid | Renewal fee | 13.02.2019 | Renewal fee patent year 03 | 13.02.2020 | Renewal fee patent year 04 | 25.02.2021 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y]EP1760088 (IMMATICS BIOTECHNOLOGIES GMBH [DE]) [Y] 1-23 * the whole document *; | [X]WO2007139260 (KOREA RES INST OF BIOSCIENCE [KR], et al) [X] 1-3,5,6* claim 21 *; | [Y]WO2011113819 (IMMATICS BIOTECHNOLOGIES GMBH [DE], et al) [Y] 1-23 * table 2; sequence 60 *; | [Y] - S. JARMALAVICIUS ET AL, "High Immunogenicity of the Human Leukocyte Antigen Peptidomes of Melanoma Tumor Cells", JOURNAL OF BIOLOGICAL CHEMISTRY, US, (20120928), vol. 287, no. 40, doi:10.1074/jbc.M112.358903, ISSN 0021-9258, pages 33401 - 33411, XP055218706 [Y] 1-23 * the whole document * DOI: http://dx.doi.org/10.1074/jbc.M112.358903 | [Y] - MICHAL BASSANI-STERNBERG ET AL, "Mass Spectrometry of Human Leukocyte Antigen Class I Peptidomes Reveals Strong Effects of Protein Abundance and Turnover on Antigen Presentation", MOLECULAR & CELLULAR PROTEOMICS, US, (20150302), vol. 14, no. 3, doi:10.1074/mcp.M114.042812, ISSN 1535-9476, pages 658 - 673, XP055272560 [Y] 1-23 * the whole document * DOI: http://dx.doi.org/10.1074/mcp.M114.042812 |